Sample Answer
Balancing the Risks and Benefits of GM Technologies in Medicine
Introduction
Genetic modification (GM) technologies have revolutionised modern medicine, offering ways to produce life-saving drugs, develop targeted therapies, and address genetic disorders at their root. However, these technologies also raise ethical, biological, and ecological concerns about their long-term safety and social impact. One of the most prominent and early examples of GM application in medicine is the use of genetically modified bacteria to produce human insulin. This innovation marked a turning point in biotechnology by enabling the mass production of pure, human-compatible insulin through recombinant DNA technology. This essay explores how GM bacteria are used to produce insulin, examining the underlying molecular biology, benefits to healthcare and patients, potential risks, and the overall balance between these factors.
The Molecular Biology of Recombinant Insulin Production
The production of insulin using GM bacteria is a landmark achievement in molecular biology. It begins with the isolation of the human insulin gene, which encodes the polypeptide hormone responsible for regulating blood glucose levels. Scientists use restriction enzymes to cut out the gene from human DNA and insert it into a bacterial plasmid, a small, circular DNA molecule separate from the main bacterial chromosome. This process uses a molecular tool called DNA ligase to bond the human gene with the plasmid DNA, creating recombinant DNA.
The modified plasmid is then introduced into Escherichia coli (E. coli) cells through a process called transformation, where bacteria take up foreign DNA. Once inside, the bacteria replicate rapidly, producing large quantities of the recombinant plasmid. As the bacterial cells grow, they express the human insulin gene and synthesise insulin molecules identical to those naturally produced by the human pancreas. The recombinant insulin is later extracted and purified for pharmaceutical use. The final product, known commercially as Humulin, was first produced by Genentech and approved for use in 1982 (Johnson, 2016).
This process replaced earlier methods that extracted insulin from the pancreases of pigs and cows. Those animal-based insulins often caused allergic reactions in humans because they were not identical to human insulin. Recombinant DNA technology solved this issue by providing a reliable, pure, and ethically acceptable source of insulin that could be manufactured at scale.
The Medical and Therapeutic Benefits of GM Insulin
The use of GM bacteria in insulin production has had transformative effects on global health. Diabetes mellitus, particularly Type 1 diabetes, affects millions of people who rely on daily insulin injections to survive. Before recombinant insulin, the global insulin supply was limited, expensive, and often impure. The use of GM bacteria enabled mass production of consistent, high-quality insulin, making treatment more affordable and accessible.
Recombinant insulin offers multiple clinical advantages. It is identical to endogenous human insulin, which eliminates the immune reactions that were common with animal-derived insulin. Furthermore, the production process allows for the creation of insulin analogues, slightly modified versions that adjust the hormone’s absorption rate, duration, and onset of action. These analogues, such as insulin lispro and insulin glargine, offer patients greater flexibility and better glycaemic control (Baeshen et al., 2014).
Beyond direct health benefits, recombinant insulin represents a major step forward in the field of pharmaceutical biotechnology. The same technology has been adapted to produce growth hormones, clotting factors for haemophilia, and vaccines, demonstrating the versatility and reliability of GM microorganisms as biofactories. Moreover, recombinant insulin paved the way for further innovation in molecular medicine, showing that genetic engineering could safely and effectively be used in healthcare.
